22.09.2011 • News • Watson Pharmaceuticals

Watson Confirms Amphastar Patent Lawsuit

Generic drug maker Watson Pharmaceuticals Wednesday confirmed that Momenta Pharmaceuticals and Sandoz have filed suit against Amphastar Pharmaceuticals and Watson on September 21 in the US District Court for the District of Massachusetts. Watson and Amphastar intend to vigorously defend the claims in the lawsuit.

The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Momenta's U.S. Patent Nos. 7,790,466 and 7,575,886. Enoxaparin Sodium Injection is a generic equivalent to Sanofi-Aventis' Lovenox.

Watson Pharmaceuticals

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.